+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Enzalutamide"

Prostate Cancer Drugs Market Report 2025 - Product Thumbnail Image

Prostate Cancer Drugs Market Report 2025

  • Report
  • April 2025
  • 175 Pages
  • Global
From
From
From
From
From
Metastatic Castration-Resistant Prostate Cancer- Pipeline Insight, 2025 - Product Thumbnail Image

Metastatic Castration-Resistant Prostate Cancer- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 240 Pages
  • Global
From
Metastatic Prostate Cancer Drug Pipeline Analysis Report 2025 - Product Thumbnail Image

Metastatic Prostate Cancer Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • June 2025
  • 200 Pages
  • Global
From
From
From
From
From
From
From
Loading Indicator

Enzalutamide is a drug used to treat prostate cancer. It is a type of androgen receptor inhibitor, which works by blocking the action of male hormones that can cause the growth of prostate cancer cells. Enzalutamide is used in combination with other treatments, such as hormone therapy, chemotherapy, and radiation therapy. It is typically prescribed to men with advanced prostate cancer that has spread to other parts of the body. Enzalutamide can help slow the progression of the disease and improve quality of life. Enzalutamide is available in both oral and injectable forms. It is generally well-tolerated, with the most common side effects being fatigue, hot flashes, and joint pain. It is important to note that Enzalutamide can cause serious side effects, including seizures, liver damage, and an increased risk of stroke. Several companies are involved in the Enzalutamide market, including Astellas Pharma, Pfizer, and AstraZeneca. These companies manufacture and distribute the drug, as well as provide support services for patients. Show Less Read more